Completed OBSERVATIONAL NCT03361111

BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment (BIOSAMOT)

Utility of Biomarkers in Evaluating Responsiveness to Anti-IgE (Omalizumab) in Severe Asthma Patients

Sponsor: Medical University of Warsaw

Updated 8 times since 2017 Last updated: Oct 10, 2019 Started: Apr 4, 2013 Primary completion: Nov 5, 2018 Completion: Dec 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Severe Asthma, this trial is completed. The trial is conducted by Medical University of Warsaw and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Nov 2019 — Jan 2021 [monthly]

Completed

Status: Recruiting → Completed
Nov 2018 — Nov 2019 [monthly]

Recruiting

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Recruiting
Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
Dec 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Warsaw

Data source: Medical University of Warsaw

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Warsaw, Poland